Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks

19 January 2021

EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed

15 January 2021

All routes to healthcare efficiency include biosimilar medicines

9 December 2020

EU Pharma Strategy: Success depends on access to Generic, Biosimilar and Value Added Medicines

25 November 2020

IGBA Launches First Global Biosimilars Week

16 November 2020

Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines

5 November 2020

Statement from the President: Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing

7 October 2020

Berlin, 07 October 2020, speaking at ‘For a Healthy Europe’, […]

COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy

9 July 2020

Urgent call for a structured industry-EU dialogue on reform The […]

IQVIA Institute Scorecards show biosimilar medicines offer win for patients, policymakers and healthcare systems across Europe

30 June 2020

Good biosimilar medicine policies balance the benefits of multi-source competition, […]

EU Pharmaceutical Strategy Roadmap: high time to improve patient access to medicines and to apply the lessons from Covid19

4 June 2020